icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
H3VnCjeMZHyQHNB2